Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
Last trade$3.01
Day change+$0.01 (+0.33%)
Day range$2.92 – $3.16
Volume85,770
Market cap$70M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$70.37M
Price / earnings
—
Price / book
2.1×
Price / sales
15.01×
EV / sales
7.37×
EV / EBITDA
-1.09×
Profitability
Earnings per share
-$1.29
Return on assets
-76.74%
Return on equity
-89.88%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.24×
Quick ratio
7.24×
Cash ratio
6.64×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$21.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COYA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$234.13K
$243.75K
$251.15K
$3.96M
$3.56M
$163.62K
$257.88K
$1.95K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$234.13K
$243.75K
$251.15K
$3.96M
$3.56M
$163.62K
$257.88K
$1.95K
Selling, general and administrative
$2.59M
$2.26M
$3.78M
$3.27M
$2.56M
$2.91M
$2.71M
$2.14M
Research and development
$8.59M
$5.03M
$4.11M
$6.71M
$3.43M
$3.66M
$5.21M
$1.94M
Total operating expenses
$11.18M
$7.29M
$7.89M
$9.99M
$6M
$6.58M
$7.93M
$4.08M
Operating income
-$10.95M
-$7.05M
-$7.64M
-$6.03M
-$2.43M
-$6.41M
-$7.68M
-$4.08M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$10.62M
-$6.64M
-$7.21M
-$5.71M
-$2.12M
-$6.09M
-$7.31M
-$3.64M
Income taxes
$0
$0
$0
$3.09K
$0
$0
$0
-$720.29K
Net income
-$10.62M
-$6.64M
-$7.21M
-$5.71M
-$2.12M
-$6.09M
-$7.31M
-$2.92M
Net income attributable to common shareholders
-$10.62M
-$6.64M
-$7.21M
-$5.71M
-$2.12M
-$6.09M
-$7.31M
-$2.92M
EBITDA
-$10.95M
-$7.04M
-$7.64M
-$6.02M
-$2.43M
-$6.41M
-$7.67M
-$4.07M
Basic earnings per share
-$0.45
-$0.28
-$0.32
-$0.34
-$0.13
-$0.36
-$0.44
-$0.18
Diluted earnings per share
-$0.45
-$0.28
-$0.32
-$0.34
-$0.13
-$0.36
-$0.44
-$0.18
Recent news
Company coverage with links to the original publishers.
The global exosome therapy market is projected to grow from $32 million in 2026 to $1.4 billion by 2040, with a CAGR of 41.1%. Key growth drivers include expanding clinical pipelines, increased regulatory filings, and rising investment in regenerative medicine. Ophthalmology and oncology represent major therapeutic areas, while Asia-Pacific is positioned as a leading market. However, challenges include inconsistent therapeutic preparations, contamination risks, and quality control complexities.
Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.
We've compiled a list of August investment picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. See their Buy recommendations here.
Within the last quarter, Coya Therapeutics (NASDAQ:COYA) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
8
0
0
0
0
Last 30D
1
0
0
0
0
1M Ago
0
0
0
0
0
2M Ago
3
0
0
0
0
3M Ago
4
0
0
0
0
According to 8 analyst offering 12-month price targets in the last 3 months, Coya Therapeutics has an average price target of $19.75 with a high of $28.00 and a low of $9.00.
Below is a summary of how these ...Full story available on Benzinga.com
Coya Therapeutics (NASDAQ:COYA) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
9
0
0
0
0
Last 30D
1
0
0
0
0
1M Ago
5
0
0
0
0
2M Ago
1
0
0
0
0
3M Ago
2
0
0
0
0
These 9 analysts have an average price target of $18.33 versus the current price of Coya Therapeutics at $4.715, implying upside.
Below is a summary of how these 9 analysts rated Coya Therapeutics over ...Full story available on Benzinga.com
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.